Dicot Pharma's clinical phase 2a study is fully enrolled and all participants have also been dosed. The company has previously communicated that the study is expected to be completed by mid-2025. As the last participant has now been dosed, the company can conclude that the study will be completed in August 2025, when the last participant’s final clinical visit takes place.

Once the study is completed, the collected data will be cleaned, the database locked, and a subsequent statistical analysis carried out before results can be reported – a process expected to take two to three months.

"We are very pleased to be able to complete this study in just nine months. It´s a strong endorsement of Clinical Trial Consultants, the CRO we´re working with. Now follows an intense period to report the outcome of the trial as soon as possible”, says Charlotta Gauffin, CSO at Dicot Pharma.

About the phase 2a study

The purpose of the phase 2a study is to evaluate the effect of LIB-01 on erectile function in men with erectile dysfunction. The study is conducted at six clinics in Sweden (Uppsala, Stockholm, Gothenburg and Linköping), Denmark (Herlev), and the Netherlands (Groningen). All participating men have erectile dysfunction and have been in a steady relationship for at least six months. Each subject participates in the study for eight weeks after dosing. The efficacy of LIB-01 is evaluated using the International Index of Erectile Function questionnaire. The trial is double blind and placebo controlled. This means that neither the clinical staff administering the study drug, nor the participants, know which subjects are receiving LIB-01 and which are receiving placebo.